Ace inhibitors and a cough
Some people notice that they get a ticklish, dry cough when they first start taking ACE-inhibitor drugs like ramipril. Usually this gets better in a few weeks as your body gets used to the new drug. Starting at a low dose and building the dose up slowly helps. More than often the cough is due to something else but in other cases it can be persistent.
It is rare for the cough to be severe and persistent from taking an ACE-inhibitor, enough to make you want to stop taking the drug, but if it is, there are several options so don’t worry. There is another class of drugs that blocks the receptor that the Angiotensin Converting Enzyme acts on. These ACE receptor blocker drugs usually end in “-artan,” so you will see names like losartan or candesartan. These drugs seem to have similar effects to the ACE-inhibitors. They do not cause a cough and are therefore easier to take for people who have trouble taking ACE-inhibitors. The ACE receptor blockers have not been on the market as long as ACE-inhibitors, and there are not as many long-term research studies about them, but what is known so far is very encouraging. Like the ACE-inhibitors, they help lower the blood pressure and seem to protect the kidneys from damage that causes you to lose protein in your urine.
The reson why these class of drugs are prescribed to heart failure patients is that “in patient speak” it widens the blood vessels and they become a little bit more elastic therefore taking some of the strain and stress off the heart as the blood vessels and arteries are wider. It is very important to keep taking your prescribed drugs but if there is a problem then there is generally another solution like mentioned above.
Amias for Chronic Heart Failure
Good news for Heart Failure patients who can’t tolerate ACE inhibitors.
Takeda has highlighted a new ruling by the National Institute for Health and Clinical Excellence (NICE) which will affect Amias, its candesartan cilexetil-based treatment for chronic heart failure patients.
The healthcare regulator has chosen to recommend angiotensin receptor blockers (ARBs) licensed for heart failure – a class of drugs which includes Amias – as an alternative first-line therapy in patients who are unable to tolerate an ACE inhibitor.
Among the factors behind this new ruling was data from clinical trials of Takeda’s drug, demonstrating its efficacy and safety among heart failure patients when compared to a placebo.
It will help to provide a new treatment option for those who are intolerant to ACE inhibitor-based treatments, which can cause coughing among many patients.
Professor John Cleland, professor of cardiology at Hull York Medical School, University of Hull, said: “Candesartan is one of the best studied ARBs and has been shown to improve symptoms, exercise capacity and morbidity.”